Navigation Links
Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
Date:5/2/2013

SAN DIEGO, May 02, 2013 /PRNewswire/ -- Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz , MBChB, D.Phil., President and CEO of Abide Therapeutics.  "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases." 

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products. Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry , Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories. "We look forward to working with Abide on the discovery and development of important new medicines."

About Serine Hydrolases

The large family of serine hydrolases are validated but largely under explored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases.  The technology provides a rapid and effective method for target identification and validation.  

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger , that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas.  Abide is located in San Diego.  To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
2. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
3. SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board
4. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
5. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
6. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
9. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
10. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
11. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... A first-time look at workers’ compensation claims in Kentucky found ... Compensation Research Institute (WCRI) announced, and that costs per claim were stable between ... Edition , found that indemnity costs per claim and benefit delivery expenses per claim ...
(Date:4/28/2016)... ... ... Metabolic Nutrition today announced the upcoming launch of its revolutionary ... Fit and Sports Expo in Orlando, Florida. Attended by pro athletes, fitness ... was selected as the perfect event to introduce the highly anticipated GlycoLoad. , ...
(Date:4/28/2016)... Louis, MO (PRWEB) , ... April 28, 2016 , ... Denise McCormick Baich had written ... in 2009 the poetry arrived again much like a tsunami and took on a more ... closest to her encouraged her to do more with it than just file it away. ...
(Date:4/28/2016)... ... ... North Hollywood dentist , Dr. Hamid Reza, now offers emergency dental ... to dental accidents or critical dental problems. These issues can threaten a person's dental ... teeth, chipped teeth, and many other issues can lead to emergency situations, and Dr. ...
(Date:4/28/2016)... ... ... The USDA recently released its updated Dietary Guidelines for Americans — advice that ... lot of information available in the report, older men should focus on four specific ... Men's Health Watch . , These include: , 1.    Vary food choices. “Mixing it ...
Breaking Medicine News(10 mins):